Next 10 |
home / stock / gsgtf / gsgtf news
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2...
Advanced discussions ongoing to secure financing until resumption of early access program (AAC/AAP) expected in Q3 2024 Full alignment sought with regulatory agencies prior to launch of a global Phase III trial supporting both US and EU regulatory submissions for registration of LUMEVOQ ...
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calen...
Efforts to reduce operational expenses confirming the cash runway until the end of April 2024 Mobilization of resources aimed at releasing the batch of LUMEVOQ® Drug Product expected in Q3 2024 to ensure the resumption of compassionate access Active discussions regarding a new financ...
Sustained efficacy 4 years after injection in REFLECT Phase III trial Continued benefit at 4 years in bilaterally treated patients: clinically meaningful improvement of at least 15 letters relative to their observed nadir 73% of bilaterally treated patients experience clinically meaningfu...
Rate of visual improvement (Clinically Relevant Recovery, or CRR) among patients treated with LUMEVOQ ® gene therapy is greater than that of idebenone-treated patients and untreated patients First set of meta-analyses to compare visual outcomes in Leber Hereditary Optic Neuropathy (L...
Clinically meaningful improvement in visual acuity confirmed in a real-world setting: on-chart mean visual acuity at 9 months after injection, compared to off-chart mean at baseline Eyes of bilaterally treated patients improve more than those of unilaterally treated patients: +23 ETDRS letter...
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific dat...
Efficacy and Safety profile of LUMEVOQ ® confirmed in a real-world setting Improvement of visual acuity of +22.5 ETDRS letters vs nadir at one year Data presented at the NANOS 2023 Annual Meeting, March 14 Regulatory News: This press release features multimedia. Vie...
Sustained efficacy three years after injection: statistically significant visual acuity improvement from nadir Continuous benefits in bilaterally treated patients with +17 to +20 ETDRS letters improvement vs nadir at 3 years 62% of bilaterally treated patients off-chart at baseline move b...
News, Short Squeeze, Breakout and More Instantly...
GenSight Biologics SA Company Name:
GSGTF Stock Symbol:
OTCMKTS Market:
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2...
Advanced discussions ongoing to secure financing until resumption of early access program (AAC/AAP) expected in Q3 2024 Full alignment sought with regulatory agencies prior to launch of a global Phase III trial supporting both US and EU regulatory submissions for registration of LUMEVOQ ...
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calen...